Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 3913-3920

  Yamazaki, Hideya ^a   Nishiyama, Kinji ^b   Tanaka, Eiichi ^b   Maeda, Osamu ^b   Meguro, Norio ^b   Kinouchi, Toshiaki ^b   Usami, Michiyuki ^b   Kakimoto, Kenichi ^b   Ono, Yutaka ^b   Nishimura, Tsunehiko ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

3 D planning; Hormonal therapy; Prostate cancer; Side effect

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT DURATION; TREATMENT PLANNING; UROGENITAL TRACT DISEASE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES;

EID: 58149172202     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Morris DE, Emami B, Mauch PM, Konski AA, Tao ML, Ng AK, Klein EA, Mohideen N, Hurwitz MD, Fraas BA, Roach M 3rd, Gore EM and Tepper JE: Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 62: 3-19, 2005.
2. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J and Horwich A: Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 353: 267-272, 1999.
3. Koper PC, Stroom JC, van Putten WL, Korevaar GA, Heijmen BJ, Wijnmaalen A, Jansen PP, Hanssens PE, Griep C, Krol AD, Samson MJ and Levendag PC: Acute morbidity reduction using 3D-RTP for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 43: 727-734, 1999.
4. Peeters ST, Hoogeman MS, Heemsbergen WD, Slot A, Tabak H, Koper PC and Lebesque JV: Volume and hormonal effects for acute-side effects of rectum and bladder during conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 63: 1142-1152, 2005.
5. Schultheiss TE, Hanks GE, Hunt MA and Lee WR: Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of prostate. Int J Radiat Oncol Biol Phys 32: 643-649, 1995.
6. Sneller ZW, Hop WC, Carpentier PJ and Schroder FH: Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study. J Urol 147: 962-966, 1992.
7. Storey MR, Pollack A, Zagars G, Smith L, Antolak J and Rosen I: Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 48: 635-642, 2000.
8. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P and Valdagni R: Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 67: 1401-1410, 2007.
9. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A and Amols HI: Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70: 1124-1129, 2008.
10. Dearnaley DP, Sydes MR, Langley RE, Graham JD, Huddart RA, Syndikus I, Matthews JH, Scrase CD, Jose CC, Logue J, Stephens RJ; RT01 Collaborators. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiother Oncol 83: 31-41, 2007.
11. Fransson P, Bergström P, Löfroth PO and Widmark A: Five-year prospective patient evaluation of bladder and bowel symptoms after dose-escalated radiotherapy for prostate cancer with the BeamCath technique. Int J Radiat Oncol Biol Phys 66: 430-438, 2006.
12. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L and Lebesque JV: Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24: 1990-1996, 2006.
13. Yoshimura R, Iwata M, Shibuya H, Sakai Y and Kihara K: Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer. Radiat Med 24: 553-559, 2006.
14. Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D and Pollack A: Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62: 397-405, 2005.
15. Sanguineti G, Agostinelli S, Foppiano F, Franzone P, Garelli S, Marcenaro M, Orsatti M and Vitale V: Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer 86: 1843-1847, 2002.
16. Labrie F: Key role of endocrinology in the victory against prostate cancer. Bull Cancer 93: 946-958, 2006.
17. Pilepich MV, Asbell SO, Krall JM, Baerwald WH, Sause WT, Rubin P, Emami BN and Pidcock GM: Correlation of radiotherapeutic parameters and treatment-related morbidity analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys 13: 1007-1012, 1987.
18. Cancer Registration Committee of the Japanese Urological Association: Clinicopathological statistics on registered prostate cancer patients in Japan 2000 report from the Japanese Urological Association. Int J Urol 12: 46-61, 2005.
19. Laverdière J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A and Labrie F: Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37: 247-252, 1997.
20. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S and Fuks Z: Three-dimensional conformai radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol 152: 1792-1798, 1994.
21. Smit WG, Helle PA, van Putten WL, Wijnmaalen AJ, Seldenrath JJ and van der Werf-Messing BH: Late radiation damage in prostate cancer patients treated by high-dose external beam radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18: 23-29, 1990.
22. Hanks GE, Schultheiss TE, Hunt MA and Epstein B: Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 31: 25-29, 1995.
23. Ogawa K, Nakamura K, Onishi H, Sasaki T, Koizumi M, Shioyama Y, Komiyama T, Miyabe Y and Teshima T: Japanese Patterns of Care Study Working Subgroup of Prostate Cancer: Radical external beam radiotherapy for prostate cancer in Japan, results of the 1999-2001 Patterns of Care Process Survey. Jpn J Clin Oncol 36: 40-45, 2006.
24. Nakamura K, Teshima T, Takahashi Y, Imai A, Koizumi M, Mitsuhashi N and Inoue T: Japanese PCS Working Subgroup of Prostate Cancer: Radical radiation therapy for prostate cancer in Japan: a Patterns of Care Study report. Jpn J Clin Oncol 33: 122-126, 2003.
25. Pollack A and Zagars GK: External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 39: 1011-1018, 1997.